CYP1, 2 and 3 family enzymes are involved in the biotransformation of xenobiotics, including clinically used drugs. CYP3A4 is the major enzyme involved in drug metabolism by the liver.

1. Daly AK. (2006) Significance of the minor cytochrome P450 3A isoforms. Clin Pharmacokinet, 45 (1): 13-31. [PMID:16430309]

2. Fontana E, Dansette PM, Poli SM. (2005) Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity. Curr Drug Metab, 6 (5): 413-54. [PMID:16248836]

3. Furster C, Wikvall K. (1999) Identification of CYP3A4 as the major enzyme responsible for 25-hydroxylation of 5beta-cholestane-3alpha,7alpha,12alpha-triol in human liver microsomes. Biochim Biophys Acta, 1437 (1): 46-52. [PMID:9931427]

4. Greenblatt DJ, Harmatz JS. (2015) Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies. Br J Clin Pharmacol, 80 (3): 342-50. [PMID:25923589]

5. Groarke DA, Drmota T, Bahia DS, Evans NA, Wilson S, Milligan G. (2001) Analysis of the C-terminal tail of the rat thyrotropin-releasing hormone receptor-1 in interactions and cointernalization with beta-arrestin 1-green fluorescent protein. Mol Pharmacol, 59 (2): 375-85. [PMID:11160875]

6. Guengerich FP, Cheng Q. (2011) Orphans in the human cytochrome P450 superfamily: approaches to discovering functions and relevance in pharmacology. Pharmacol Rev, 63 (3): 684-99. [PMID:21737533]

7. Guengerich FP, Martin MV, Beaune PH, Kremers P, Wolff T, Waxman DJ. (1986) Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem, 261 (11): 5051-60. [PMID:3514607]

8. Kharasch ED, Mitchell D, Coles R, Blanco R. (2008) Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir. Antimicrob Agents Chemother, 52 (5): 1663-9. [PMID:18285471]

9. Sevrioukova IF, Poulos TL. (2015) Current Approaches for Investigating and Predicting Cytochrome P450 3A4-Ligand Interactions. Adv Exp Med Biol, 851: 83-105. [PMID:26002732]

10. Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD, Wrighton SA. (2002) Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos, 30 (8): 883-91. [PMID:12124305]

11. Zhou SF. (2008) Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab, 9 (4): 310-22. [PMID:18473749]